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Table 1.
Age
Nadir
wbc Nadir plt
Days to
wbc>1
Days to CD34>10,
median (quartiles)
Days between
wbc>1 to 34>10,
median (quartiles)
Good (n5370) 58 0.3 68 11 12 (11-13) 0 (0-1)
Poor (n526) 64 0.2 30 12 13 (13-16) 2 (2-3.5)
P value 0.003 0.07 0.02 0.03 0.01 0.0005
Optimal (n5340) 58 0.3 67 11 12 (11-13) 0 (0-1)
Suboptimal (n530) 65 0.3 83 12 14 (11.75-15) 1.5 (0.75-2)
P Value >0.05 0.3 0.5 0.1 0.0001 0.0001
Optimal <3apheresis (n5307) 58 0.3 67 11 11 (11-13) 0 (0-0)
Optimal >3 apheresis (n533) 59 0.4 80 12 14 (12-16.75) 2 (0-3.75)
P Value >0.05 0.2 0.9 0.2 0.0001 0.0001
Good: CD34+cells>2x106/kg, Poor: CD 34+ cells <2x106/kg, Optimal: CD34+cells >5x106/kg, Suboptimal: CD34+cells: 2-5x106/kg
Poster Session I S203factors for outcome CY-mob. If a higher CD341 cell count is tar-
geted for transplantation (. 5x106/kg), the delay in the days to
CD341 cells. 10 in peripheral blood can be considered to be a rea-
son formodifying themobilization regimen, like adding plerixafor. If
the CD34 count is still\ 10 one day after the day WBC . 1.0, ad-
dition of plerixafor to the mobilization regimen should be strongly
considered.134
AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
IN THE ERA OF NOVEL AGENTS: IMPACT OF DEPTH OF RESPONSE TO IN-
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Background: High-dose chemotherapy and autologous stem cell
transplantation (ASCT) in newly diagnosed multiple myeloma is
the standard of care for eligible patients. Prior to ASCT, induction
therapy is administered for 1 to 4 months before stem cell collection.
Eligible patients undergo ASCT regardless of the response to induc-
tion therapy because it has been shown that a good response is not
essential in order to obtain survival benefit from ASCT. A recent
study that evaluated the novel agents, thalidomide and lenalidomide
demonstrated that failure to achieve a partial response after induc-
tion therapy predicts a poorer outcome after ASCT.
Methods: Fifty patients (60% male; median age 59 years) with mul-
tiple myeloma who underwent high-dose chemotherapy and ASCT
after induction therapy with thalidomide, lenalidomide or bortezo-
mib were retrospectively studied. The patients were divided into
two groups according to their response after induction therapy:
those with CR or VGPR; and those with PR or less than PR. Statis-
tical analyses were performed.
Results:The median follow up was 33.4 (2.9-71.2) months. TheM-
protein at diagnosis was 3.46 1.7 g/dl and the stage (Durie-Salmon)
of the multiple myeloma was IIIa in 33 (66%) and IIIb in 9 (18%) pa-
tients. Beta-2 microglobulin was 4.96 4.7 g/ml and 40% of patients
had unfavorable cytogenetics defined as 13q- by cytogenetics, t
(4,14), t(14,16), 17p- and complex karyotype. Favorable cytogenetics
included normal, t(11,14) or 13q- by FISH. The induction therapy
was thalidomide in 23 (46%), lenalidomide in 9 (18%), bortezomib
in 8 (16%) and a combination in 10 (20%). The patients who
achievedCR orVGPR after induction therapywere 23 (46%). These
responses were associated with longer time to progression (HR 5
0.42; p5 0.055) after ASTC.The progression-free survival (PFS) es-
timates for CR or VGPR vs PR or\PR were 48.6 months and 21.5
months respectively (p 5 0.013). The presence of favorable cytoge-
netics was associated with a longer time to progression (HR5 0.345;
p5 0.0174). A higher beta-2 microglobulin was associated with ear-
lier time to progression (HR 5 1.073; p 5 0.0272).
Conclusion: Achieving CR or VGPR with the novel agents prior to
ASCT predicts a better PFS after transplantation. This suggests thatextending induction therapy to achieve CR or VGPR prior to ASCT
might be beneficial. Larger studies are needed to confim this finding.135
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Background: High dose melphalan (HDM) is a commonly utilized
conditioning regimen prior to autologous peripheral blood stem cell
transplantation (PBSCT) for multiple myeloma and primary amy-
loidosis. Although cardiotoxicity from this regimen has not been de-
scribed, there are multiple anecdotal cases of transient
cardiomyopathy following HDM in the Mayo Clinic transplant ex-
perience. Thus, we reviewed our experience to determine the fre-
quency of cardiomyopathy in this setting.
Methods: From our database of all patients undergoing autologous
PBSCT for myeloma or amyloidosis from 1989-2009, we identified
those with echocardiograms performed before and within 4 months
of PBSCT, and reviewed these for evidence of cardiomyopathy, de-
fined as a decrease in left ventricular ejection fraction (LVEF) of $
10% to a value of # 50%. Charts of patients meeting these criteria
were reviewed to determine conditioning regimen, pre-existing car-
diac risk factors and other potential causes of cardiomyopathy to de-
termine the association between the cardiomyopathy and HDM.
Results:Of 1476 patients (1050 myeloma; 426 amyloidosis) who re-
ceived HDM as a component of conditioning prior to PBSCT, 407
had echocardiography before and within 4months after PBSCT, and
40 (2.7%) met criteria for cardiomyopathy. When accounting for
other risk factors, HDMwas felt to be a probable cause of cardiomy-
opathy in 16 patients, a possible cause in 18, and an unlikely cause in
6. Cardiomyopathy was noted more frequently in patients undergo-
ing PBSCT for amyloidosis (23/426, 5.4%) than myeloma (17/1050,
1.6%). All 23 patients with amyloidosis received HDM alone as con-
ditioning (dose range 140-200 mg/m2). Fifteen of the 17 myeloma
patients received HDM alone as conditioning (dose range 140-200
mg/m2), with two patients receiving HDM in concert with total
body irradiation and ibritumomab, respectively.
The mean pre-PBSCT LVEF in this cohort was 59% (range 42-
70%), which decreased to a mean of 38% (range 15-50%) following
PBSCT. Diagnosis of cardiomyopathy was made within 30 days of
PBSCT in 65% (26/40) of patients. Follow up echocardiography
was performed in 26 patients, with 15 showing improvement in
LVEF to $ 50%.
Conclusion: To our knowledge, this is the first series to report car-
diomyopathy following HDM conditioning. Further work should
focus on identifying pre-transplant variables which may predispose
patients to cardiotoxicity following conditioning with HDM.
